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L domainavian sarcoma virus (ASV) Gag protein binds Nedd4 ubiquitin ligase E3 family
members and is the determinant of efﬁcient virus release in avian and mammalian cells. We previously
demonstrated that Nedd4 and Tsg101 constitutively interact raising the possibility that Nedd4 links ASV Gag
to the ESCRT machinery. We now demonstrate that covalently linking Tsg101 to ASV Gag lacking the Nedd4
binding site (Δp2b-Tsg101) ablates the requirement for Nedd4, but the rescue of budding occurs by use of a
different budding mechanism than that used by wild type ASV Gag. The evidence that Tsg101 and Nedd4
direct release by different pathways is: (i) Release of the virus-like particles (VLPs) assembled from Gag in
DF-1, an avian cell line, was resistant to dominant-negative interference by a Tsg101 mutant previously
shown to inhibit release of both HIV and Mo-MLV. (ii) Release of VLPs from DF-1 cells was resistant to siRNA-
mediated depletion of the endogenous pool of Tsg101 in these cells. (iii) VLPs assembled fromwild-type ASV
Gag exhibited highly efﬁcient release from endosome-like membrane domains enriched in the tetraspanin
protein CD63 or a ﬂuorescent analogue of the phospholipid phosphatidylethanolamine. However, the VLPs
assembled from the L domain mutant Δp2b or a chimeric Δp2b-Tsg101 Gag lacked these domain markers
even though the chimeric Gag was released efﬁciently compared to the Δp2b mutant. These results suggest
that Tsg101 and Nedd4 facilitate Gag release through functionally exchangeable but independent routes
and that Tsg101 can replace Nedd4 function in facilitating budding but not directing through the same
membranes.
© 2008 Elsevier Inc. All rights reserved.IntroductionExpression of the retroviral structural precursor polyprotein, Gag,
is sufﬁcient for the production of non-infectious viral-like particles
(VLPs; Gottlinger, 2001). Gag contains 3 distinct domains necessary for
virus assembly and budding (Wills and Craven, 1991). The membrane-
binding (M) domain mediates the association of Gag to the plasma
membrane via a cluster of basic residues and, in some retroviruses, a
myristic acid moiety co-translationally added to the N-terminus of the
Gag precursor (Spearman et al., 1994; Zhou and Resh, 1996). The
interaction (I) domain promotes Gag–Gag multimerization crucial for
particle assembly (Burniston et al., 1999; Cimarelli et al., 2000;
Sanderfur et al., 1998) and the late assembly (L) domain facilitates the
pinching off of viral particles from the plasma membrane (Gottlinger
et al., 1991; Xiang et al., 1996; reviewed in Bieniasz, 2006). L domains
have been identiﬁed in all retroviruses studied to date, as well as inStony Brook University, Stony
er).
l rights reserved.other families of enveloped viruses, such as the Rhabdoviruses, Para-
myxoviruses, and Filoviruses (Bieniasz, 2006). Retroviral L domains
are categorized into three classes, deﬁned by their conserved amino
acid core sequence: the Pro-Thr-X-Pro (usually PTAP)motif (Gottlinger
et al., 1991); the Pro-Pro-X-Tyr (PY) motif (Wills et al., 1994); and the
Tyr-X-X-Leu (YXXL) motif (Puffer et al., 1997). Acting as docking sites
for cellular proteins, L domains recruit components of the endocytic
trafﬁcking pathway to execute the ﬁssion of viral from cellular mem-
branes during the budding process (Garrus et al., 2001; Kikonyogo
et al., 2001; Martin-Serrano et al., 2001, 2003; Strack et al., 2003;
VerPlank et al., 2001; von Schwedler et al., 2003).
Through the PTAP motif, HIV-1 Gag binds directly to Tsg101
(Garrus et al., 2001; Martin-Serrano et al., 2001; VerPlank et al., 2001).
Genetic screening utilizing the yeast two-hybrid assay identiﬁed ~20
proteins involved in vacuolar protein sorting that function in
conjunction with Tsg101 [von Schwedler et al., 2003]. Disrupting the
normal function of these vacuolar protein sorting (vps) proteins,
termed “class E” Vps proteins, induces formation of abnormally
enlarged endosomes (class E compartments) in which Vps proteins
become trapped (Raymond et al., 1992) and VLP release is conse-
quently blocked. The class E Vps proteins function in complexes called
endosomal sorting complex required for transport (ESCRT)-0, -1, -2,
31G. Medina et al. / Virology 377 (2008) 30–38and -3, whichmay normally be sequentially recruited from the cytosol
to deliver cargo to the late endosome/multivesicular body (LE/MVB)
compartment where it is sorted for delivery to its ultimate destina-
tion. In yeast, the destination is most often vacuoles (equivalent to
lysosomes). The ESCRT complexes associated with the limiting
membrane of late endosomes are released back into the cytosol
through the action of the AAA ATPase Vps4 (Babst et al., 1998). Vps4
containing mutations that disrupt its ATPase activity are dominant
negative inhibitors of VLP release (Garrus et al., 2001; Medina et al.,
2005).
Tsg101 is a component of ESCRT-I that recognizes cargo proteins
modiﬁed by ubiquitin, triggering the ESCRT machinery to induce
MVB biogenesis (Bishop et al., 2002; Katzmann et al., 2001). PY
motifs bind directly to members of the Nedd4 family of HECT
ubiquitin (E3) ligases, which ubiquitinate cargo destined for delivery
to degradative compartments. Nedd4 may therefore function
upstream of Tsg101 and the other ESCRT proteins in the assembly
and release pathway of ASV. Tsg101 and Nedd4 associate constitu-
tively in the cytoplasm (Medina et al., 2005), however, Tsg101 also
has been found to associate with several other E3 enzymes (Amit et
al., 2004; Kim et al., 2007; Li et al., 2001). Here, we demonstrate that
release of ASV Gag from avian cells is insensitive to dominant
negative-interference or depletion of Tsg101, indicating that ASV Gag
release may not require Tsg101 for budding. Also, although release of
chimeric ASV Gag lacking the Nedd4 binding site was rescued by
translational fusion to Tsg101, the particles containing Tsg101 lacked
the markers of transit through endosome-like membrane domains
that characterized wild-type ASV Gag release. Interestingly, the
particles assembled from another ESCRT-1 component, Vps37C,
behaved similarly while chimeric VLPs formed with an ESCRT-2 or
an ESCRT-3 factor behaved like the wild-type. Together, these
ﬁndings suggest that although the Tsg101- and Nedd4-directed
pathways are functionally exchangeable in the release process, the
cellular proteins facilitate release through independent mechanisms
and different membrane domains.
Results
Co-expression of ASV Gag with a dominant negative interference
fragment of Tsg101 (Tsg-DN) in avian cells did not reduce ASV release
efﬁciency
Our previous ﬁndings showed that fragments of Tsg101 that inhibit
release of HIV-1 and Mo-MLV Gag in a dominant-negative manner
failed to appreciably inhibit ASV Gag release from 293E or COS-1 cells
[Medina et al., 2005 and data not shown]. In this study, we examined
ASV release from avian DF-1 cells (Himly et al., 1998; Schaefer-Klein
et al., 1998). The same Tsg101 fragment used in the previous study
(Tsg-DN; Medina et al., 2005) was transfected into the DF-1 cells. The
fragment induced the formation of large, aberrant structures in the
cytoplasm Fig. 1, panel A), as was previously observed in both avian
and mammalian cells (Goila-Gaur et al., 2003; Johnson et al., 2005;
Medina et al., 2005). The Tsg101 fragment was then co-transfected
with GFP-tagged ASV Gag (containing a D37Smutation to inactive PR),
and viral particles were harvested from the media fraction 48 h later.
As shown in the Western blot in Fig. 1B and the semi-quantitative
analysis of VLP release in Fig. 1C, virus release from DF-1 cells was
resistant to dominant negative interference by the Tsg101 fragment. In
a separate experiment, DF-1 cells constitutively expressing ASV (DF1/
RCASPB(A) (Himly et al., 1998; Schaefer-Klein et al., 1998) were mock-
transfected or transfected with DNA encoding Tsg-DN and examined
by electron microscopy after thin sectioning (panel D, left and right,
respectively). Fully assembled particles were observed outside of the
mock-transfected and the Tsg-DN-transfected cells (enlarged in insets
D1 and D2, respectively). The effect of expression of the Tsg-DN in DF-
1/RCASPB(A) cells can be seen in the right panel in D, whereaggregates of particles are detected inside of cells (enlarged in inset
D3). These aggregates were not observed in the mock transfected cells
(left panel). Taken together with the results in 293E and COS-1 cells
(Medina et al., 2005), these observations suggest that ASV Gag
assembly and release is resistant to any disruption of the endocytic
machinery that expression of the Tsg101 fragment may cause in these
cells.
Depletion of endogenous Tsg101 did not inhibit ASV Gag release
To further examine whether VLP release requires Tsg101 function,
we determined the effect of siRNA-mediated depletion of the
endogenous pool of Tsg101 in DF-1 cells on ASV Gag release. We
used a siRNA sequence designed to speciﬁcally target avian Tsg101
expression. Gag proteins in lysates prepared from gag-transfected
cells and VLP in media were harvested at 48 h post-transfection as
described in Materials and methods and analyzed by SDS-PAGE and
Western blotting. As shown in Fig. 2 (panel A), treatment with Tsg101-
speciﬁc siRNA (20 or 50 nM) was sufﬁcient to deplete cells of ~90% of
the Tsg101 protein compared to the same amount of control, non-
targeting siRNA (compare lanes 1 and 2 to lanes 3 and 4, respectively).
Under these conditions, the steady-state level of actin and the
amount of Gag detected in the lysate were not detectably reduced.
The signiﬁcant depletion of endogenous Tsg101 also failed to inhibit
ASV Gag release. A semi-quantitative analysis (VLP/Cell lysate+VLP)
panel B) indicated that the budding efﬁciency of ASV VLPs was not
signiﬁcantly different from control levels. These results indicate that
WT ASV Gag release is not dependent on the steady-state level of
Tsg101 in its natural host cell and suggest that budding may occur
independently of Tsg101 and therefore, perhaps, the ESCRT-I
complex.
Tsg101 replaced Nedd4 function in ASV Gag budding
Taken together, the observed resistance of ASV Gag budding to co-
expression with Tsg-DN and to siRNA-mediated Tsg101 depletion
indicates that ASV Gag is not strongly dependent on Tsg101 for release.
To determinewhether Tsg101 could substitute for Nedd4 inmediating
the release function, the protein was translationally fused to the C-
terminus of Gag-Δp2b, an L domain mutant that lacks the Nedd4
docking site, to form a chimeric Gag protein, Δp2b-Tsg101 (described
in Materials and methods). As avian Tsg101 has not been isolated,
human (293E), rather than avian, cells were used for these experi-
ments so that the Tsg101 in the chimeric Gag protein, the Tsg101 being
tested for its effect in trans (i.e., adventitiously expressed Tsg101), and
the Tsg101 in the cytoplasm would all be identical sequences. As
shown in Fig. 3, VLPs assembled from wild-type (WT) ASV Gag were
released into the media with high efﬁciency (panel A) in the absence
(lane 1) or presence (lane 2) of adventitious Tsg101 expression,
consistent with previous ﬁndings (Medina et al., 2005). The L domain
mutant Δp2b was released at b10% of WT efﬁciency (Kikonyogo et al.,
2001;Medina et al., 2005) and this level was the samewhether Tsg101
was expressed or not (lanes 3 and 4). Translational fusion of Tsg101 to
the Gag-Δp2b mutant to form Gag Δp2b-Tsg101 resulted in produc-
tion of signiﬁcantly more VLPs (lane 5), indicating that the release
function was rescued, however, the wild-type level was never
achieved. An estimate of VLP release efﬁciency indicated that VLPs
containing the chimeric ASV Gag protein budded at a level of ~50%
compared to WT protein (panel B) (n=4). Consistent with previous
ﬁndings (Martin-Serrano and Bieniasz, 2003), we observed that
translational fusion of Tsg101 to an L domain mutant of HIV-1 Gag
(P7L-Tsg101) resulted in efﬁcient rescue (panel B inset). Although the
level of rescue obtained for ASV Gag-Δp2b was lower than that ob-
tained for HIV-1 Gag P7L under similar conditions, the results never-
theless indicate that Tsg101 can replace the Nedd4 function required
for ASV Gag budding.
32 G. Medina et al. / Virology 377 (2008) 30–38Tsg101 and Nedd4 direct VLP release from different membrane
microdomains
Tsg101 and Nedd4 may direct release through functionally un-
linked pathways. If so, a switch from the Nedd4-dependent mechan-ism to a Tsg101-dependent mechanism might be accompanied by
changes in Gag trafﬁcking. We therefore tested for changes in Gag
delivery to the budding site using asmembranemarkers the endosomal
lipid tracer, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[lissamine rhodamine B sulfonyl] (N-Rh-PE), a ﬂuorescent
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al., 1990) or the tetraspanin protein CD63, a marker of late endosome
(LE) membranes found at steady-state mostly on LE/multivesicular
body (LE/MVB) compartments but also on the plasma membrane
(Nydegger et al., 2003, 2006). To do these experiments, 24 h post-
transfection N-Rh-PE was added to the media for 1 h at 4 °C, the cells
were then washed, and incubated an additional 24 h at 37 °C. In all
cases, VLPs isolated from the media were puriﬁed through sucrose
cushions, spun onto poly-lysine-coated coverslips, and examined by
deconvolution confocal microscopy. As shown in Fig. 4A, only small
amounts of the markers were detected in the VLPs formed when
HIV-1 Gag was expressed alone. VLPs assembled from P7 L-GFP or
P7L-Tsg101 also contained little N-Rh-PE (panels B and C) or CD63
(not shown).
To examine the VLPs assembled from ASV Gag, COS-1 cells were
transfected with DNA encoding the WT Gag, the L domain mutant
(Δp2b), or the chimeric Gag protein (Δp2b-Tsg101) and labeled with
N-Rh-PE in the same manner as the cells described above expressing
HIV-1 Gag. Fig. 5 shows images representative of the samples in at
least three independent experiments. In contrast to HIV-1 Gag, most
of the particles assembled from WT ASV Gag-GFP contained the lipid
marker (82%, n=300), as indicated by the co-localization of the Gag-
GFP and the rhodamine (red) ﬂuorescence of N-Rh-PE in yellow
particles (Fig. 5, panel C). The ﬂuorescent signal was speciﬁc, as no
signal was detected in mock-treated control samples derived from
untransfected cells similarly treated with N-Rh-PE (panel A). In
contrast to WT ASV particles, few VLPs assembled from the Δp2b-
GFPmutant (panel B) contained the tracer (7%; n=375), indicating that
these particles were not released from the same membrane region as
WT VLPs and suggesting that Nedd4 binding is necessary for
association with such membranes. Consistent with this supposition,
WT but not Δp2b co-localized with N-Rh-PE-positive membranes in
the cytoplasm (not shown). VLPs released from cells expressing the
chimeric Δp2b-Tsg101 protein were detected by indirect immuno-
ﬂuorescence using antibody against the MA domain in Gag (panel D).
Like the ASV Δp2b VLPs, few particles assembled from the chimeric
Δp2b-Tsg101 Gag protein contained the N-Rh-PE tracer (1%, n=650).
Similar results were obtained by fusing Vps37C (panel E). Interestingly,
N-Rh-PE was detected in VLPs released from cells expressing Δp2b
fused to Eap20 (panel F; 55%, n=180) or Chmp4B (panel F, inset; 40%,
n=20). These results suggest that the WT and the chimeric VLPs
containing Tsg101 or its binding partner Vps37C were released from
different membrane regions. Apparently, Nedd4 was necessary for
association with the membrane domains containing N-Rh-PE. Eap20
or Chmp4B could substitute for Nedd4 in this regard.
If Nedd4, but not Tsg101, indeed directs ASV VLP release from
endosome-likemembrane domains, CD63might also be present in the
particles. VLPs, isolated as described above, were therefore examined
for CD63 by indirect immunoﬂuorescence. As shown in panel G, VLPs
assembled from WT ASV Gag contained the tetraspanin protein in
amounts ranging from 10% (n=150) to 40% (n=150), supporting the
conclusion that the particles budded through endosome-like mem-
brane domains. In contrast, no CD63 was detected in VLPs assembled
from Δp2b (not shown) or Δp2b-Tsg101 (panel H). The absence of both
N-Rh-PE andCD63 fromthese particles supports thenotion thatNedd4
directs Gag to endosome-likemembrane domainswhile in its absence,Fig. 1. Co-expression of ASV Gag and Tsg-DN in avian cells does not reduce ASV release efﬁ
showing proximal untransfected cells and cells expressing TRITC-tagged Tsg-DN (red). Das
structures within the cell. Panel B, DF-1 cells were mock-transfected (lane 1) or transfected w
gag, 4 μg:1 μg; lane 4, 2 μg:1 μg; lane 5,1 μg:1 μg). Media and cell lysate fractions were harvest
and methods. Total cell lysates were immunoprecipitated overnight with anti-RSV polyclona
MAmonoclonal antibody. TsgDN expressionwas determined byWestern analysis of the cell l
semi-quantitative analysis of VLP release (VLP/Cell lysate+VLP). The panels show the ratio of
of the Gag signals in cell lysate plus VLP (n=2). Panel D, electron microscopy of mock-transfe
cells transfectedwith DNA encoding TsgDN (right). Cells were prepared for thin section EM as
D1, D2: Virus particles in extracellular space; D3, particles in intracellular vesicle.either by deletion of the Nedd4 docking site or by substitution of
Tsg101, Gag associates with a different membrane region.
Discussion
Unlike PTAP- and YPDL-type L domains, which bind Tsg101
(Vps23) and Alix (Vps31), respectively, and therefore directly link
Gag to class E Vps proteins, the PY-type L domains, which bind the
Nedd4 family of HECT ubiquitin ligases (Kikonyogo et al.; 2001; Vana
et al., 2004), must access the MVB machinery in a different way.
Previously, we established that Nedd4-like proteins bind to Tsg101
and that this interaction allows ASV Gag to co-localize with Tsg101
(Medina et al., 2005). This might provide ASV Gag with access to the
Tsg101-directed pathway and to ESCRT factors that it requires for
budding, such as Eap20 (Pincetic, Medina, Carter, and Leis, submitted).
We showed here that ASV Gag release from avian cells was not
blocked following co-expression of Gagwith Tsg-DN or by depletion of
the endogenous pool of Tsg101. Similar interventions have been
shown to inhibit release of HIV-1 Gag from primate cells (Garrus et al.,
2001; Goila-Gaur et al., 2003; Medina et al., 2005 and data not shown).
Tsg-DN has been shown to induce formation of aberrant endosomes
that disrupt endocytic sorting (Goila-Gaur et al., 2003; Johnson et al.,
2005). We detected similar aberrant structures in DF-1 cells. Never-
theless, we observed no inhibition of ASV Gag release. We demon-
strated that Tsg101 can replace Nedd4 and rescue Δp2b release
(Fig. 3). This observation suggests that the function of Nedd4 in ASV
release can be replaced by Tsg101 and most likely explains the well-
documented functional exchangeability of the HIV-1 and ASV L do-
mains (Parent et al., 1995). However, our studies now provide
evidence that the L domain contributes to membrane targeting as
we found that different outcomes result from Nedd4-, Eap20-, or
Chmp4B- vs Tsg101- or Vps37C-facilitated budding. It is interesting
that neither Tsg101 nor Vps37C, which are linked in ESCRT-1, rescued
the membrane targeting of WT ASV Gag. In contrast, this functionwas
rescued by Eap20 and Chmp4B, which are linked through Chmp6
(Yorikawa et al., 2005).
Although the translational fusionof Tsg101 toGag-Δp2b restoredGag
release, it placed Tsg101 on every Gag molecule, raising the possibility
that potential steric effects hindered an association between the chimeric
Gag proteins and membranes containing N-Rh-PE or CD63. This
possibility is unlikely because the chimeric Gag proteins were found to
associate with N-Rh-PE- and CD63-positive membranes in the cytoplasm
(data not shown). Moreover, we showed that the translational fusion of
Eap20 or Chmp4B to Gag-Δp2b restored both release and WT targeting.
Most likely, Tsg101 and Nedd4 do not direct ASV trafﬁcking via the same
routeasweobserved thatdepletionofTsg101wasnoteffective inblocking
release of the WT ASV Gag compared to the previously described effect
(Garrus et al., 2001) of Tsg101 depletion on HIV Gag release. As already
noted,Nedd4 function is apparently not requiredwhenTsg101 is provided
in cis (Pincetic, Medina, Carter, and Leis, submitted). These considerations
lead us to conclude that Nedd4 family members direct release through a
pathway that functionally parallels that directed by Tsg101. The fact that
neither Δp2b-Tsg101 nor -Eap20 form a stable complex with Nedd4
(Pincetic, Medina, Carter, Leis) suggests that Nedd4may not be needed to
enter thepathways they target. Perhaps sharedbindingpartners normally
providea conduit toTsg101andESCRT-regulated trafﬁckingpathways. It isciency. Panel A, confocal microscopy of DF-1 cells transfected with Tsg-DN. Left, ﬁeld
hed lines show cell outline. Right, same ﬁeld showing localization of Tsg-DN-induced
ith DNA encoding ASV gag (lanes 2–5) and the indicated ratio of Tsg-DN (lane 3, TsgDN:
ed at 48 h post-transfection. VLPs were isolated from themedia as described inMaterials
l antibody. Gag protein in VLPs and lysates were detected by immunoblotting with anti-
ysate, using a monoclonal antibody against the myc tag on the Tsg101 fragment. Panel C,
the Gag signal (determined using NIH image) in VLP isolated from the media to the sum
cted DF-1 cells constitutively expressing ASV [DF-1/RCASBP(A), left] or DF-1/RCASBP(A)
described inMaterials andmethods. Arrows denote regions enlarged in the insets. Inset,
Fig. 2. Depletion of endogenous Tsg101 in DF-1 cells by siRNA-targeting. Panel A, DF-1
cells were transfectedwith Tsg101-speciﬁc siRNA (lanes 1 and 2) or control siRNA (lanes
3 and 4) for 48 h followed by transfectionwith DNA encoding ASVGag-GFP for 24 h. Gag
proteins in lysates and media were isolated as described in Materials and methods and
analyzed by SDS-PAGE and Western blotting. The endogenous Tsg101 level in each
sample was determined by Western analysis of the total lysate. Panel B, semi-
quantitative analysis of ASV Gag release efﬁciency.
Fig. 3. Translational fusion of Tsg101 to the C-terminus of ASV Gag Δp2b rescues VLP
release. Panel A, 293/E cells were transfected with DNA encoding WT ASV Gag (lanes 1
and 2) or L domain-deleted (Δp2b) ASV Gag (lanes 3 and 4) alone (lanes 1 and 3) or with
DNA encoding HA-Tsg101 (lanes 2 and 4). Lane 5, cells were transfected with DNA
encoding Gag-Δp2b-Tsg101. Cells were harvested 48 h later and examined by Western
blotting. Panel A, top: cell lysate probed for Gag; middle: cell lysate probed for HA-
Tsg101; bottom: VLP probed for Gag. Panel B, semi-quantitative analysis of ASV VLP
release efﬁciency. Inset, rescue efﬁciency of P7 L-Tsg101.
34 G. Medina et al. / Virology 377 (2008) 30–38interesting to note that release of HIV with L domain mutations has been
demonstrated to be rescued by over-expression of Nedd4-like variants
(Chung et al., 2008; Usami et al., 2008). Over-expression of these variants
in cells expressing HIV-1 Gag with Tsg101 and AIP-1 binding site
mutations was found to rescue VLP release. Over-expression or depletion
of the variants had no detectable effect on WT HIV-1, suggesting that
rescue represents an alternative mechanism that the virus uses to release
from cells. As noted above, Tsg101 is known to bind several E3 proteins in
the cytoplasm, including avian Nedd4. As we found no requirement for
Tsg101, it is unlikely that the interaction plays a critical role in the release
function. Although the precise site of interaction between Tsg101 and
Nedd4-like proteins has not beenmapped,we showedpreviously that the
interaction utilized the C-terminal region of Tsg101 and the N-terminal
portion of the Nedd4 protein (Medina et al., 2005). This indicates that the
interaction is not a canonical E2-E3 interaction, which would require the
N-terminal ubiquitin-E2-like (UEV) domain in Tsg101 and the C-terminalcatalytic (HECT) domain in Nedd4. In contrast, the rescue of the L domain
defect of HIV by the variants cited above requires the ubiquitin–ligase
activity of the enzyme (Chung et al., 2008; Usami et al., 2008). Even if
Nedd4 recognizes Tsg101 as an E2 homologue, Nedd4-directed ASV Gag
release need not be dependent on Tsg101 if Nedd4, like Tsg101, interacts
with other ESCRT proteins.
The differences in use of membrane sites for budding by ASV and
HIV-1 Gag may be related to the fact that the M domain membrane
transport signals of ASV and HIV-1 Gag differ. The former is found in
basic residues in the MA coding sequence and in the fourth alpha
helix (Scheifele et al., 2003) while the latter is found in a bipartite
motif comprised of basic residues and an N-terminal myristic acid
moiety (Zhou et al., 1994). Moreover, Nedd4, which is recruited by the
L domain located downstream of MA in the Gag precursor
(Kikonyogo et al., 2001), contains a membrane-binding C2 domain
(Dunn et al., 2004) that may direct ASV Gag to speciﬁc areas of the
plasma membrane. This notion is supported by the observation that
Gag, which binds the WW domain in Nedd4 (Kikonyogo et al., 2001),
co-localized with the protein in different subcellular locations,
depending on the presence or absence of the Nedd4 C2 domain
(data not shown). We speculate that the combination of trafﬁcking
signals in both Nedd4 and ASV Gag transports these proteins to
Fig. 4. Examination of WT and chimeric HIV-1 VLPs for N-Rh-PE. VLPs released from
COS-1 cells transfected with DNA encoding WT HIV-1 Gag-GFP (panel A), P7L-Gag
(panel B), or P7L-Tsg101 Gag (panel C) were isolated from the media as described in the
text, spun onto poly-lysine-coated coverslips, and examined for the presence of N-Rh-
PE. Panels A, C inset: higher magniﬁcation. The bar in panels A and C measures 200 nm.
35G. Medina et al. / Virology 377 (2008) 30–38different membrane sites for budding than the signals that direct
HIV-1 Gag transport. It will be of interest to determine speciﬁcally
how ESCRT factors versus Nedd4 family members facilitate trafﬁcking
and release of ASV Gag.Materials and methods
Constructs and reagents
The following plasmids were previously described: pCMV-HIV-1gag
or pCMV-ASVgag encoding HIV-1 andASV Gag C-terminally taggedwith
green ﬂuorescent protein (Gag-GFP;Medina et al., 2005); DNA encoding
HA-Tsg101 (Lu et al., 2003); andDNA encodingmyc-tagged fragments of
Tsg101 (Li et al., 2001). DNA encoding ASV Gag Δp2b-Tsg101 was
constructed as follows: p2036 (Kikonyogo et al., 2001) was doubly
digestedwith KpnI andXbaI to remove the gfp coding region. Using PCR-
basedmethods, a 5′KpnI sitewas introducedupstreamof the start codon
ofASVGag-Δp2b. Additionally, a 3′HpaI sitewas introduceddownstream
of the ASV Gag-Δp2b coding sequence. Similarly, a 5′ HpaI and a 3′XbaI
sitewere introduced upstreamanddownstream, respectively, of the full-
length coding sequence of tsg101. Both PCRproductswere then ligated to
the KpnI and XbaI doubly digested p2036 vector DNA to produce p2036
ASVgag-Δp2b-tsg101, in which Tsg101 is translationally fused in the
correct reading frame to the C-terminus of ASV Gag-Δp2b. An identical
strategy was followed to construct the HIVgag P7L-tsg101 fusion con-
struct and the ASVgag-Δp2b-vps37C, -Δp2b-eap20, and -chmp4B con-
structs. The following probes were purchased as indicated: Antibodies
recognizing: actin, CD63, Tsg101, myc (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); GFP (Clontech Laboratories, Mountain View, CA, USA);
inﬂuenza virus HA (Covance, Berkeley, Calif.); TRITC-tagged second-
ary antibody (Molecular Probes); and 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[lissamine rhodamine B sulfonyl] (N-Rh-PE;
Molecular Probes). Anti-AMV MA (p19) monoclonal antibody, which
recognizes ASVMA,was developed by David Boettiger andwas obtained
from the Developmental Studies Hybridoma Bank under the auspices of
the NICHD and maintained by the University of Iowa, Department of
Biological Sciences. (Iowa City, IA, USA).
Cell culture, transfection, preparation of cytoplasmic extracts, and virus
isolation
COS-1, 293/E, DF-1, or DF-1/RCAS/BP(A) cells were cultured in
DMEM supplemented with fetal bovine serum (5%, 10%, 10%, and 10%,
respectively) and antibiotics to 60% conﬂuency at 37 °C. The relatively
high ratio of cytoplasm to nucleus and ability to spread on tissue
culture plates and coverslipsmake COS-1 cells advantageous for use in
imaging studies. Expression of plasmids in the p2036 background was
higher in 293/E cells (described in Kikonyogo et al., 2001) because
293/E cells stably express the EBNA1 protein of EBV and the p2036
constructs contain the EBV FR plasmid maintenance element that
EBNA 1 binds. Therefore 293/E cells were used when proteins
expressed from p2036 were to be detected by Western analysis.
Unless otherwise indicated, the cells were transfected by using the
FuGene 6 reagent (Roche, Indianapolis, IN, USA) according to the
instructions of the manufacturer. At 48 h post-transfection, the cells
were washed with phosphate-buffered saline (PBS) and lysed with
RIPA buffer (1% lgepal CA-630, 0.5% sodium deoxychlolate, and 0.1%
SDS in 1× PBS) containing protease inhibitor cocktail tablets (Roche)
for 15 min at 4 °C. The lysate was then passaged through a 21-gauge
needle and incubated on ice for 60 min. Cellular debris was pelleted at
10,000 ×g for 10min at 4 °C (lysate fraction). ASVGagwas identiﬁed by
Western blotting using speciﬁc anti-MA (ASV) monoclonal antibody.
To isolate VLPs, the cell culture media was ﬁltered (0.25 μm), applied
to a cushion of 20% sucrose in a centrifuge tube and then spun at
30,000 rpm for 80 min at 4 °C (Beckman SW41 rotor). The pelleted
particles were suspended by gentle shaking at 4 °C in 50 μl of PBS or
RIPA buffer containing protease inhibitor cocktail. Samples were
analyzed by SDS-PAGE and Western analysis. Equivalent amounts of
cell lysates and of media fractions were used for all samples. Semi-
quantitative determinations of VLP release (VLP/cell lysate+VLP ratio)
were made using a phosphorimager and NIH Image.
Fig. 5. Examination of WT and chimeric ASV VLPs for N-Rh-PE and CD63. VLPs frommock-transfected COS-1 cells (panel A) or cells transfected with DNA encoding WT ASV Gag-GFP
(panels C and G), Gag Δp2b (panel B), Gag Δp2b-Tsg101 (panels D and H), GagΔp2b-Vps37C (panel E) or GagΔp2b-Eap20 (panel F) were isolated from the media as described in the
text, spun onto poly-lysine-coated coverslips, and examined for the presence of N-Rh-PE directly or for CD63 by indirect immunoﬂuorescence. The scale bar in the panel or inset
measures 200 nm. Insets, panels C, F, and G show co-localizing Gag-GFP (left), N-Rh-PE (middle, panels C and F) or CD63 (middle, panel G), and merged images (right) for VLPs. The
inset below panel F shows the same for GagΔp2b-Chmp4B VLPs. Insets, panels B, D, E, and H show the ﬂuorescent signals in VLPs where GFP and N-Rh-PE or CD63 did not co-localize.
In panels C and F, the magniﬁcation is the same in the panel and inset.
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We obtained 21 nt RNA duplexes with symmetric 3′-UU overhangs
corresponding to coding nucleotides 326–344 of avian Tsg101
(GUACUGUCCCGGUGAAAUA; Dharmacon, Lafayette, CO, USA). 20 or
50 nM of Tsg101 siRNA or a non-targeting control siRNA were trans-
fected into DF-1 cells in six-well plates using Lipofectamine RNAiMax
(Invitrogen, Carlsbad, CA, USA). 48 h post-siRNA transfection, DF-1
cells were transfected with p2036 encoding WT ASV Gag using
FuGene 6. 24 h later, VLPs were pelleted through a 20% sucrose
cushion at 100,000 ×g for 1 h. ASV Gag expression and VLP release
were analyzed by Western blotting with anti-AMV p19 monoclonal
antibody. The endogenous level of avian Tsg101 was analyzed by
Western blotting with anti-Tsg101 antibody raised against full-length
Tsg101 of mouse origin, which cross-reacts with mammalian and
avian Tsg101.
Fluorescence microscopy
Fluorescent microscopy images were captured with an inverted
ﬂuorescent/dic Zeiss Axiovert 200 M microscope equipped with an
AxioCam HRm camera (Zeiss, Thornwood, NY, USA) and mercury arc
lamp light source using a 63× Plan-Apochromat (NA 1.40) oil objective
and operated by AxioVision Version 4.5 (Zeiss) software.
Electron Microscopy
Sixty-millimeter dishes of DF1/RCASBP(A) cells were washed
with PBS at room temperature and ﬁxed in 2.5% glutaraldehyde in
0.1 M sodium phosphate buffer (pH 7.4) at 4 °C for 30 min. Cells
were scraped from the tissue culture dish and pelleted at 1000 ×g
for 10 min at 4 °C. The cell pellet was ﬁxed for an additional 2 h in
2.5% glutaraldehyde and post-ﬁxed for 1 h with osmium tetroxide.
The cell pellet was dehydrated in a series of alcohol washes and
embedded in Epon. Ultrathin sections were stained with uranyl
acetate and lead citrate and examined using a Zeiss 900 electron
microscope.
Protein detection
Proteins were separated by electrophoresis through 12.5% SDS-
polyacrylamide gels. Following electrophoresis, the gels were trans-
ferred to nitrocellulose and analyzed by Western blotting with the
antibodies speciﬁed in the text. Proteins were visualized by chemi-luminescence using Lumi-Light reagents (Roche, Indianapolis, IN,
USA).
Acknowledgments
This work was supported by National Institutes of Health grants
AI068463 (to CC) and AI054143 (to JL). GM was supported in part by a
W. Burghardt Turner Pre-doctoral Fellowship, the NSF-HRD funded
SUNY AGEP Program at Stony Brook University, Grant #35583 and by
NIH Pre-Doctoral Training grant 5T32 CA-09176. AP is supported by
the NIH pre-doctoral Training Grant T32 AI060523.
References
Amit, I., Yakir, L., Katz, M., Zwang, Y., Marmor, M.D., Citri, A., Shtiegman, K., Alroy, I.,
Tuvia, S., Reiss, Y., Roubini, E., Cohen, M., Wides, R., Bacharach, E., Schubert, U.,
Yarden, Y., 2004. Tal, a Tsg101-speciﬁc E3 ubiquitin ligase, regulates receptor endo-
cytosis and retrovirus budding. Genes Dev. 18, 1737–1752.
Babst, M.B., Wendland, B., Estepa, E.J., Emr, S.D., 1998. The Vps4p AAA ATPase regulates
membrane association of a Vps protein complex required for normal endosome
function. EMBO J. 17, 2982–2993.
Bieniasz, P., 2006. Late budding domains and host proteins in enveloped virus release.
Virology 344, 55–63.
Bishop, N., Horman, A., Woodman, P., 2002. Mammalian class E vps proteins recognize
ubiquitin and act in the removal of endosomal protein ubiquitin conjugates. J. Cell
Biol. 157, 91–101.
Burniston, M., Cimarelli, A., Colgan, J., Curtis, S.P., Luban, J., 1999. Human immunode-
ﬁciency virus type 1 Gag polyprotein multimerization requires the nucleocapsid
domain and RNA and is promoted by the capsid-dimer interface and the basic
region of matrix protein. J. Virol. 73, 8527–8540.
Chung, H.Y., Morita, E., von Schwedler, U., Müller, B., Kräusslich, H.G., Sundquist, W.I.,
2008. NEDD4L Overexpression Rescues Release and Infectivity of HIV-1 Constructs
Lacking PTAP and YPXL Late Domains. J. Virol. 82, 4884–4897.
Cimarelli, A., Sandlin, S., Hoglund, S., Luban, J., 2000. Basic residues in human
immunodeﬁciency virus type 1 nucleocapsid promote virion assembly via
interaction with RNA. J. Virol. 74, 3046–3057.
Dunn, R., Klos, D.A., Adler, A.S., Hicke, L., 2004. The C2 domain of the Rsp5 ubiquitin
ligase binds membrane phosphoinositides and directs ubiquitination of endosomal
cargo. J. Cell Biol. 165, 135–144.
Garrus, J., von Schwedler, U.K., Pornillos, O.W., Morham, S.G., Zavitz, K.H., Wang, H.E.,
Wettstein, D.A., Stray, K.M., Cote, M., Rich, R.L., Myszka, D.G., Sunquist,W.I., 2001. Tsg101
and the vacuolar protein sorting pathways are essential for HIV budding. Cell 107,
55–65.
Goila-Gaur, R., Demirov, D.G., Orenstein, J.M., Ono, A., Freed, E.O., 2003. Defects in
human immunodeﬁciency virus budding and endosomal sorting induced by Tsg101
overexpression. J. Virol. 77, 6507–6519.
Gottlinger, H., 2001. The HIV 1 assembly machine. AIDS 15, 13–20.
Gottlinger, H., Dorfman, T., Sodroski, J.G., Haseltine, W.A., 1991. Effect of mutations
affecting the p6 Gag protein on human immunodeﬁciency virus particle release.
Proc. Natl. Acad. Sci. U. S. A. 88, 3195–3199.
Himly, M., Foster, D.N., Bottoli, I., Iacovoni, S., Vogt, P.K., 1998. The DF-1 chicken
ﬁbroblast cell line: Transformation-induced by diverse oncogenes and cell death
resulting from infection by avian leucosis viruses. Virology 248, 295–304.
38 G. Medina et al. / Virology 377 (2008) 30–38Johnson, M.C., Spidel, J.L., Ako-Adjei, D., Wills, J.W., Vogt, V.M., 2005. The C-terminal half
of Tsg101 blocks Rous sarcoma virus budding and sequesters Gag into unique
nonendosomal structures. J. Virol. 79, 377–386.
Katzmann, D., Babst, M., Emr, S.D., 2001. Ubiquitin dependent sorting into the mul-
tivesicular body pathway requires the function of a conserved endosomal protein
sorting complex ESCRT-1. Cell 106, 145–155.
Kikonyogo, A., Bouamr, F., Vana, M.L., Xiang, Y., Aiyar, A., Carter, C., Leis, J., 2001. Proteins
related to the Nedd4 family of ubiquitin protein ligases interact with the L domain
of Rous sarcoma virus and are required for Gag budding from cells. Proc. Natl. Acad.
Sci. U. S. A. 98, 11199–11204.
Kim, B.Y., Olzmann, J.A., Barsh, G.S., Chin, L.S., Li, L., 2007. Spongiform neurogeneration-
associated E3 ligase Mahogunin ubiquitylates Tsg101 and regulates endosomal
trafﬁcking. Mol. Biol. Cell 18, 1129–1142.
Li, L., Liao, J., Ruland, J., Mak, T., Cohen, S.N., 2001. A Tsg101/MDM2 regulatory loop
modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad.
Sci. U. S. A. 98, 1616–1624.
Lu, Q., Hope, W., Brasch, M., Reinhrad, C., Cohen, S.N., 2003. Tsg101 interaction with Hrs
mediates endosomal trafﬁcking and receptor down-regulations. Proc. Natl. Acad.
Sci. U. S. A. 100, 7626–7631.
Martin-Serrano, J., Bieniasz, P.D., 2003. A bipartite late-budding domain in HIV-1 type 1.
J. Virol. 77, 12373–12377.
Martin-Serrano, J., Zang, T., Bieniasz, P.D., 2001. HIV 1 and Ebola encode small peptide
motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med.
7, 1313–1319.
Martin-Serrano, J., Yarovoy, A., Perez Caballero, D., Bieniasz, P.D., 2003. Divergent
retroviral late budding domains recruit vacuolar protein sorting factors by using
alternative adaptor proteins. Proc. Natl. Acad. Sci. U. S. A. 100, 12412–12419.
Medina, G., Zhang, Y., Tang, Y., Gottwein, E., Vana, M.L., Bouamr, F., Leis, J., Carter, C.A.,
2005. The functionally exchangeable L domains in RSV and HIV-1 Gag direct
particle release through pathways linked by Tsg101. Trafﬁc 6, 880–894.
Nydegger, S., Foti, M., Derdowski, A., Spearman, P., Thali, M., 2003. HIV-1 egress is gated
through late endosomal membranes. Trafﬁc 4, 902–910.
Nydegger, S., Khurana, S., Krementsov, D.N., Foti, M., Thali, M., 2006. Mapping of
tetraspanin-enriched microdomains that can function as gateways for HIV-1. J. Cell
Biol. 173, 795–807.
Parent, L., Bennett, R.P., Craven, R.C., Nelle, T.D., Krishna, N.K., Bowzard, J.B., Wilson, C.B.,
Puffer, B.A., Montelaro, R.C., Wills, J.W., 1995. Positionally independent and
exchangeable late budding functions of the Rous sarcoma virus and human
immunodeﬁciency virus Gag proteins. J. Virol. 69, 5455–5460.
Puffer, B., Parent, L.J., Wills, J.W., Montelaro, R.C., 1997. Equine infectious anemia virus
utilizes a YXXLmotif within the late assembly domain of the Gag p9 protein. J. Virol.
71, 6541–6546.
Raymond, C.K., Howarld-Stevenson, I., Vater, C.A., Stevens, T.H., 1992. Morphological
classiﬁcation of the yeast vacuolar protein sorting mutants: evidence for a
prevacuolar compartment in class E vps mutants. Mol. Biol. Cell 3, 1389–1402.
Sanderfur, S., Varthakavi, V., Spearman, P., 1998. The I domain is required for efﬁcient
plasma membrane binding of human immunodeﬁciency virus type 1 Pr55Gag.
J. Virol. 72, 2723–2732.Schaefer-Klein, J., Givol, I., Barsov, E.V., Whitcomb, J.M., Van-Brocklin, M., Foster, D.N.,
Fedspiel, M.J., Hughes, S.H., 1998. The EV-0-derived cell line DF-1 supports the
efﬁcient replication of avian leucosis-sarcoma viruses and vectors. Virology 248,
305–311.
Scheifele, L.Z., Rhoads, J.D., Parent, L.J., 2003. Speciﬁcity of plasma membrane targeting
by the Rous sarcoma virus gag protein. J. Virol. 77, 470–480.
Spearman, P., Wang, J., Vander Heyden, N., Ratner, L., 1994. Identiﬁcation of human
immunodeﬁciency virus type 1 Gag protein domain essential to membrane binding
and particle assembly. J. Virol. 68, 3232–3242.
Strack, B., Calistri, A., Craig, S., Popova, E., Gottlinger, H.G., 2003. AIP-1/ALIX is a
binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114,
689–699.
Usami, Y., Popov, S., Popova, E., Göttlinger, H.G., 2008. Efﬁcient and speciﬁc rescue of
human immunodeﬁciency virus type 1 budding defects by a Nedd4-like ubiquitin
ligase. J. Virol. 82, 4898–4907.
Vana, M.L., Chen, A., Medina, G., Carter, C., Leis, J., 2004. Role of Nedd4 and
ubiquitination of Rous sarcoma virus Gag in budding of virus-like particles from
cells. J. Virol. 78, 13943–13953.
VerPlank, L., Bouamr, F., LaGrassa, T.J., Agresta, B., Kikonyogo, A., Leis, J., Carter, C.A.,
2001. Tsg101, a homologue of ubiquitin conjugating (E2) enzymes, binds the L
domain in HIV type 1 Pr55 (Gag). Proc. Natl. Acad. Sci. U. S. A. 98, 7724–7729.
Vidal, M., Mangeat, P., Hoekstra, D., 1997. Aggregation reroutes molecules from a
recycling to a vesicle mediated secretion pathways during reticulocyte maturation.
J. Cell Sci. 110, 1867–1877.
von Schwedler, U., Stuchell, M., Muller, B., Ward, D.M., Chung, H.Y., Morita, E.,
Wang, H.E., Davis, T., He, G.P., Cimbora, D.N., Scott, A., Krausslich, H.G., Kaplan, J.,
Morham, S.G., Sundquist, W.I., 2003. The protein network of HIV budding. Cell 114,
701–713.
Willem, J., Beest, M., Scherphof, G., Hoekstra, D., 1990. A non-exchangeable ﬂuorescent
phospholipid analog as a membrane trafﬁc marker of the endocytic pathway. Eur. J.
Cell Biol. 53, 173–184.
Wills, J., Craven, R.C., 1991. Form, function and use of retroviral Gag proteins. AIDS 5,
639–654.
Wills, J., Cameron, C.E., Wilson, C.B., Xiang, Y., Bennett, R.P., Leis, J., 1994. An assembly
domain of the Rous sarcoma virus Gag protein required late in budding. J. Virol. 68,
6605–6618.
Xiang, Y., Cameron, C., Wills, J., Leis, J., 1996. Fine mapping and characterization of the
Rous sarcoma virus Pr76gag late assembly domain. J. Virol. 70, 5695–5700.
Yorikawa, C., Shibata, H., Waguri, S., Hatta, K., Horii, M., Katoh, K., Kobayashi, T.,
Uchiyama, Y., Maki, M., 2005. Human CHMP6, a myristoylated ESCRT-III protein,
interacts directly with an ESCRT-II component EAP20 and regulates endosomal
cargo sorting. Biochem. J. 387, 17–26.
Zhou, W., Resh, M.D., 1996. Differential membrane binding of the human immunode-
ﬁciency virus type 1 matrix protein. J. Virol. 70, 8540–8548.
Zhou, W., Parent, L.J., Wills, J.W., Resh, M.D., 1994. Identiﬁcation of a membrane-
binding domain within the amino terminal region of human immunodeﬁciency
virus type 1 Gag protein which interacts with acidic phospholipids. J. Virol. 68,
2556–2569.
